00

Jiangsu Nhwa Pharmaceutical Co LtdSHE 002262 Stock Report

Last reporting period 30 Jun, 2024

Updated 28 Oct, 2024

Last price

Market cap $B

3.541

Middle

Exchange

XSHE - Shenzhen Stock Exchange

002262.SZ Stock Analysis

00

Uncovered

Jiangsu Nhwa Pharmaceutical Co Ltd is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

105/100

High score

Market cap $B

3.541

Dividend yield

1.30 %

Shares outstanding

1 007.59 B

Jiangsu Nhwa Pharmaceutical Co., Ltd. engages in the pharmaceutical production, research and development, and sales. The company is headquartered in Xuzhou, Jiangsu and currently employs 4,732 full-time employees. The company went IPO on 2008-07-23. The firm offers its pharmaceutical products under four categories, which consist of anesthetic medicines, including midazolam injections and etomidate fat emulsion pharmaceutical preparations injections; psychiatric medicines, including risperidone tablets and others; neurological medicines, including gabapentin capsules and others; bulk drugs, including fenofibrate and miconazole nitrate. The firm is also engaged in the pharmaceuticals trading business. Through its subsidiaries, the Company is also engaged in the Internet medical businesses. The firm distributes its products within domestic market and to overseas markets.

View Section: Eyestock Rating